Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong demand for its cancer and rare diseases medicines, after third-quarter results beat estimates.

AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to commit significant new spending to the country after Donald Trump’s election win. The decision to go ahead with the spending ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped analysts’ expectations.

KEY TAKEAWAYS British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.